OncoImmune: Merck, expanding coronavirus work, buys a small biotech and its COVID-19 drug
The large drugmaker will pay $425 million to acquire OncoImmune, which is developing a treatment for severe coronavirus disease.
Read full article »
OncoImmune is a biopharmaceutical company that develops and commercializes immunotherapies for the treatment of cancer and autoimmune diseases.
Read more